1147 related articles for article (PubMed ID: 32075939)
1. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
3. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
5. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
Front Immunol; 2021; 12():703986. PubMed ID: 34484200
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
9. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
11. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
[TBL] [Abstract][Full Text] [Related]
12. A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.
Domi A; Feldmann F; Basu R; McCurley N; Shifflett K; Emanuel J; Hellerstein MS; Guirakhoo F; Orlandi C; Flinko R; Lewis GK; Hanley PW; Feldmann H; Robinson HL; Marzi A
Sci Rep; 2018 Jan; 8(1):864. PubMed ID: 29339750
[TBL] [Abstract][Full Text] [Related]
13. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
[TBL] [Abstract][Full Text] [Related]
15. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
[TBL] [Abstract][Full Text] [Related]
16. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
17. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
[TBL] [Abstract][Full Text] [Related]
18. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.
Warfield KL; Dye JM; Wells JB; Unfer RC; Holtsberg FW; Shulenin S; Vu H; Swenson DL; Bavari S; Aman MJ
PLoS One; 2015; 10(3):e0118881. PubMed ID: 25793502
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
20. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
